Shire's ADHD deal with Actavis cuts risk
This article was originally published in Scrip
Executive Summary
In settling with Actavis over US patent litigation concerning the attention deficit hyperactivity disorder (ADHD) drug Intuniv (guanfacine hydrochloride), Shire has traded the possibility of stronger sales until mid-2016 for the certainty that Actavis will not launch until 1 December 2014.